Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 5,146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults

NCT02474901
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Quadrivalent Live Attenuated Influenza Vaccine
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 25 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Not applicable Interventional

Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users

NCT01343654
View directory record Official record
Conditions
HIV Infections
Interventions
Text messaging plus EMA, Treatment as usual
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 26, 2026, 7:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols

NCT00026754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Sarcoma, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month and older
Enrollment
19,522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Media HIV Prevention Intervention for High Risk Rural Women

NCT03456453
View directory record Official record
Conditions
HIV/AIDS
Interventions
NIDA Standard for HIV Prevention
Behavioral
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 7:42 AM EDT
Completed No phase listed Observational

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

NCT01180075
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV), tenofovir/emtricitabine (TDF/FTC), Atazanavir (ATV), Ritonavir, Phlebotomy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 1 Interventional

A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection

NCT00000669
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Not applicable Interventional

A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)

NCT00002254
View directory record Official record
Conditions
HIV Infections
Interventions
Alovudine
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 1Phase 2 Interventional

Culturally Sensitive Intervention to Improve Retention in HIV Care for Latino MSM

NCT01457066
View directory record Official record
Conditions
HIV
Interventions
Peer Navigator Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

NCT00959894
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (Intelence), Truvada
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

NCT03960645
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 39 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

NCT01854775
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
E/C/F/TAF, E/C/F/TAF (Low Dose)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Atazanavir and Endothelial Function in Older HIV Patients

NCT03019783
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children

NCT00000983
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
48
States / cities
Downey, California • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

NCT00412477
View directory record Official record
Conditions
HIV Infections
Interventions
HIV LFn-p24
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 26, 2026, 7:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

NCT06501781
View directory record Official record
Conditions
HIV Infections, Substance Use
Interventions
Peer Activate-LAI, Standard of Care HIV treatment or prevention with LAI-PrEP/ART
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK

NCT04064567
View directory record Official record
Conditions
HIV/AIDS, Pre-exposure Prophylaxis
Interventions
PrEP-LINK, Enhanced Standard of Care
Behavioral · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
7
States / cities
Little Rock, Arkansas • West Memphis, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Not applicable Interventional Results available

HIV-related Insomnia and Inflammation

NCT04721067
View directory record Official record
Conditions
Hiv, Insomnia
Interventions
SHUTi, Sleep Education/Hygiene
Device · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 26, 2026, 7:42 AM EDT
Completed No phase listed Observational

Gonorrhea and Chlamydia HIV-infected Men Who Have Sex With Men

NCT02019771
View directory record Official record
Conditions
HIV Infection, Chlamydia, Gonorrhea
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

NCT00036634
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir DF, Tenofovir alafenamide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 26, 2026, 7:42 AM EDT
Completed No phase listed Observational

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

NCT00776412
View directory record Official record
Conditions
Inflammation, Pathologic Processes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

NCT00006436
View directory record Official record
Conditions
Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
Interventions
Rituximab, Filgrastim, EPOCH
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 26, 2026, 7:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor

NCT04870671
View directory record Official record
Conditions
HIV/AIDS, Adherence, Medication, Drug Use
Interventions
Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 26, 2026, 7:42 AM EDT